MarketWatch
Real-time markets & breaking news
After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring
By Steve Goldstein
Read original article on MarketWatch
Just days after a capital-markets day left investors wondering what’s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.
This story was originally published on MarketWatch. DennTech aggregates headlines from top crypto publications to keep traders informed.
Read full article on MarketWatch